GBP5 and triple-negative breast carcinoma: Previous studies have shown that GBP5 can promote the malignant progression of oral squamous cell carcinoma, triple-negative breast cancer, and glioblastoma (Cheng et al., 2021b; Liu et al., 2021; Yu et al., 2021).